Iohexol vs. metrizamide: Study of efficacy and morbidity in cervical myelography

Richard E Latchaw, W. L. Hirsch, J. A. Horton, D. Bissonette, D. D. Shaw

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


A double-blind study was conducted in 60 patients undergoing either cervical or more complete myelography via C1-C2 puncture. Patients received either iohexol or metrizamide at a 300 mg l/ml concentration. The contrast media were equally efficacious in the production of high-quality radiographs and CT scans. However, the incidence of adverse reactions differed markedly. Of patients receiving metrizamide, 68% had some type of adverse reaction, whereas only 26% receiving iohexol had symptoms. The incidence of headache (metrizamide, 34%; iohexol, 26%) was not statistically different, but the quality of the headache differed: half of the metrizamide headaches were moderate or severe, whereas all iohexol headaches were mild. Nausea (31%) and vomiting (28%) were common with metrizamide but unusual (3% nausea) with iohexol. Of the metrizamide patients, 21% had overt psychologic changes that did not occur in the iohexol group.

Original languageEnglish (US)
Pages (from-to)931-934
Number of pages4
JournalAmerican Journal of Neuroradiology
Issue number6
StatePublished - 1985
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology


Dive into the research topics of 'Iohexol vs. metrizamide: Study of efficacy and morbidity in cervical myelography'. Together they form a unique fingerprint.

Cite this